Vice President, Clinical Development
About this role
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
Tango Therapeutics is seeking a visionary and strategic oncology leader to serve as Vice President, Clinical Development. Reporting directly to the President of Research & Development, this highly visible executive will lead the clinical development strategy from early stage through late stage development.
This role offers the opportunity to shape enterprise-wide clinical development strategy, build high-performing development capabilities, and play a pivotal role in advancing transformational therapies for patients with cancer.
Your Role:
As Vice President, Clinical Development, you will provide strategic and scientific leadership for the clinical development of vopimetostat. Reporting to the President of Research & Development, you will lead the development and execution of the Clinical Development Plan for the program and serve as the clinical development leader on the Global Program Team. Working closely with cross-functional partners, you will drive clinical strategy, ensure the successful execution of clinical studies, and integrate emerging clinical, translational, regulatory, and competitive insights to inform key development decisions. You will also lead, mentor, and develop a team of Medical Directors and Clinical Scientists and represent Tango within the oncology community to advance innovative therapies for patients with cancer.
- Lead the clinical development strategy for vopimetostat, including ownership of the Clinical Development Plan and its evolution throughout development
- Serve as the Clinical Development leader and a core member of the Global Program Team, partnering cross-functionally to shape program strategy and deliver development milestones
- Lead the design, execution, analysis, and interpretation of clinical studies, including protocol development, dose optimization, indication expansion, and data-driven decision making
- Lead, mentor, and develop a team of Medical Directors and Clinical Scientists, fostering a culture of scientific excellence, collaboration, accountability, and continuous learning
- Partner with Project Management, Clinical Operations, Regulatory Affairs, Clinical Pharmacology, Biometrics, Translational Medicine, Medical Writing, and Pharmacovigilance to ensure aligned, high-quality program execution
- Lead clinical contributions to regulatory interactions and oversee preparation and review of protocols, Investigator's Brochures, INDs/CTAs, briefing packages, and marketing application components
- Interpret emerging clinical, safety, PK/PD, biomarker, and competitive data to refine development strategy and inform program decisions
- Build and maintain strong relationships with key opinion leaders, investigators, and external collaborators
- Represent Tango at regulatory meetings, scientific congresses, investigator meetings, and advisory boards
- Support scientific communications, including publications, abstracts, and presentations
What You Bring:
- MD with board certification (or eligibility) in Medical Oncology or a related specialty
- 14+ years of oncology drug development experience within the biotechnology and/or pharmaceutical industry, spanning early- and late-stage clinical development
- Demonstrated success leading clinical development programs, including development of Clinical Development Plans, protocol design, execution of clinical trials, and experience with regulatory interactions and NDA/BLA submission
- Expertise designing and executing biomarker-driven oncology clinical trials
- Experience leading, mentoring, and developing physicians and/or Clinical Scientists within a matrixed drug development organization
- Deep understanding of oncology drug development, ICH-GCP, FDA, and global regulatory requirements
- Strong scientific and clinical judgment, with the ability to integrate clinical, safety, pharmacology, biomarker, and competitive data to inform development strategy
- Exceptional communication, collaboration, and cross-functional leadership skills, with the ability to influence across diverse scientific and operational teams
- Resourceful, adaptable, and execution-oriented, with a passion for advancing innovative therapies for patients with cancer
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Company at a glance
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
Tired of cold applications?
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Know someone who'd be great for this?